Voorbeelden van het gebruik van Vemurafenib in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Vemurafenib inhibited CYP2C8 in vitro.
Zelboraf 240 mg tablets vemurafenib.
Effects of vemurafenib on CYP substrates.
Concurrent administration with vemurafenib.
Vemurafenib is a moderate CYP1A2 inhibitor.
Zelboraf 240 mg film-coated tablets vemurafenib.
Effects of vemurafenib on other medicinal products.
Effect of other medicinal products on vemurafenib.
Maintain vemurafenib at a dose of 960 mg twice daily.
Effects of concomitant medicines on vemurafenib.
Vemurafenib is an inhibitor of BRAF serine-threonine kinase.
Carcinogenicity studies have not been conducted with vemurafenib.
Vemurafenib is a substrate and inhibitor of P-gp in vitro.
Zelboraf is a medicine that contains the active substance vemurafenib.
Interaction of vemurafenib with drug transport systems.
Accumulation occurs upon multiple twice daily dosing of vemurafenib.
Cotellic treatment and vemurafenib treatment should be interrupted.
Dose modification advice for Cotellic when used with vemurafenib.
The dose of vemurafenib may be reduced as clinically appropriate.
Cotellic is used in combination with another medicine called vemurafenib.
Cotellic in combination with vemurafenib in patients with brain metastases.
Vemurafenib dosing can be continued when Cotellic treatment is modified if clinically indicated.
The absolute bioavailability of the vemurafenib 240 mg tablet is unknown.
Vemurafenib dosing should be reduced as clinically appropriate,
The effect of food on steady state vemurafenib exposure is currently unknown.
After cessation of vemurafenib treatment, a washout of 8 days might be necessary to avoid an interaction with a subsequent treatment.
Dose modification of Cotellic is independent of vemurafenib dose modification.
efficacy of the combination of Cotellic and vemurafenib have not been evaluated in patients with a BRAF V600 mutation-positive melanoma which has metastasised to the brain.
Exercise caution and consider additional INR(International Normalised Ratio) monitoring when vemurafenib is used concomitantly with warfarin.
It is currently unknown whether vemurafenib is a substrate also to other transport proteins.